Carnitine palmitoyltransferase II deficiency

WikiDoc Resources for Carnitine palmitoyltransferase II deficiency
Articles
Most recent articles on Carnitine palmitoyltransferase II deficiency Most cited articles on Carnitine palmitoyltransferase II deficiency Review articles on Carnitine palmitoyltransferase II deficiency Articles on Carnitine palmitoyltransferase II deficiency in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Carnitine palmitoyltransferase II deficiency Images of Carnitine palmitoyltransferase II deficiency Photos of Carnitine palmitoyltransferase II deficiency Podcasts & MP3s on Carnitine palmitoyltransferase II deficiency Videos on Carnitine palmitoyltransferase II deficiency
Evidence Based Medicine
Cochrane Collaboration on Carnitine palmitoyltransferase II deficiency Bandolier on Carnitine palmitoyltransferase II deficiency TRIP on Carnitine palmitoyltransferase II deficiency
Clinical Trials
Ongoing Trials on Carnitine palmitoyltransferase II deficiency at Clinical Trials.gov Trial results on Carnitine palmitoyltransferase II deficiency Clinical Trials on Carnitine palmitoyltransferase II deficiency at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Carnitine palmitoyltransferase II deficiency NICE Guidance on Carnitine palmitoyltransferase II deficiency NHS PRODIGY Guidance FDA on Carnitine palmitoyltransferase II deficiency CDC on Carnitine palmitoyltransferase II deficiency
Books
Books on Carnitine palmitoyltransferase II deficiency
News
Carnitine palmitoyltransferase II deficiency in the news Be alerted to news on Carnitine palmitoyltransferase II deficiency News trends on Carnitine palmitoyltransferase II deficiency
Commentary
Blogs on Carnitine palmitoyltransferase II deficiency
Definitions
Definitions of Carnitine palmitoyltransferase II deficiency
Patient Resources / Community
Patient resources on Carnitine palmitoyltransferase II deficiency Discussion groups on Carnitine palmitoyltransferase II deficiency Patient Handouts on Carnitine palmitoyltransferase II deficiency Directions to Hospitals Treating Carnitine palmitoyltransferase II deficiency Risk calculators and risk factors for Carnitine palmitoyltransferase II deficiency
Healthcare Provider Resources
Symptoms of Carnitine palmitoyltransferase II deficiency Causes & Risk Factors for Carnitine palmitoyltransferase II deficiency Diagnostic studies for Carnitine palmitoyltransferase II deficiency Treatment of Carnitine palmitoyltransferase II deficiency
Continuing Medical Education (CME)
CME Programs on Carnitine palmitoyltransferase II deficiency
International
Carnitine palmitoyltransferase II deficiency en Espanol Carnitine palmitoyltransferase II deficiency en Francais
Business
Carnitine palmitoyltransferase II deficiency in the Marketplace Patents on Carnitine palmitoyltransferase II deficiency
Experimental / Informatics
List of terms related to Carnitine palmitoyltransferase II deficiency

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Carnitine palmitoyltransferase II deficiency
Carnitine
ICD-9	277.85
OMIM	255110
DiseasesDB	32534
eMedicine	ped/321

Overview

Carnitine palmitoyltransferase II deficiency is a condition that prevents the body from converting certain fats called long-chain fatty acids into energy, particularly during periods without food. Carnitine, a natural substance acquired mostly through the diet, is used by cells to process fats and produce energy. People with this disorder have a faulty enzyme that prevents these fats from being processed in the mitochondria.

Classification

Types

There are three main types of carnitine palmitoyltransferase II deficiency:

• a lethal neonatal form
• a severe infantile hepatocardiomuscular form,
• a myopathic form

Neonatal form

Infants with the lethal neonatal form of this disorder usually experience respiratory failure, liver failure, seizures, and an irregular heart beat leading to cardiac arrest. In many cases, patients have malformed features and an abnormally developed brain and kidneys.

Hepatocardiomuscular type

Signs and symptoms of the infantile hepatocardiomuscular type usually appear between 6 and 24 months of age. This condition involves recurring attacks of abnormally low levels of fat breakdown products and blood sugar (hypoketotic hypoglycemia) causing a loss of consciousness and seizures. Liver failure and an enlarged liver (hepatomegaly) are also sometimes seen. In many cases, there is also heart involvement. Episodes are often triggered by infections, fever, or fasting.

Myopathic form

The myopathic form is the most frequently seen and least severe form of carnitine palmitoyltransferase II deficiency. It has a variable age of onset and is characterized by muscle pain (myalgia) and weakness. This condition is sometimes associated with the abnormal breakdown of an oxygen-binding muscle protein called myoglobin (myoglobinuria). Myoglobinuria can cause kidney failure and death.

Causes

Mutations in the CPT2 gene cause carnitine palmitoyltransferase II deficiency, leading to the production of a defective version of an enzyme called carnitine palmitoyltransferase II.

Without this enzyme, long-chain fatty acids from food and fats stored in the body cannot be broken down and processed.

Excessive levels of long-chain fatty acids may build up in tissues, damaging the heart, liver, and muscles and causing more serious complications.

This condition is inherited in an autosomal recessive pattern.

See also

• Primary carnitine deficiency
• Carnitine palmitoyltransferase I deficiency

This article incorporates public domain text from The U.S. National Library of Medicine

References

Template:WikiDoc Sources